In a recent study, the use of cabozantinib after progression of renal cell carcinoma (RCC) was assessed. Forty-five (45) patients continued with treatment with cabozantinib after their disease had progressed, and 44 patients switched to cabozantinib. Nearly 60% of patients had been treated with two or more prior treatments. Of these patients, most (85%) had […]
In a recent study, the researchers looked at the RNA in renal cell carcinoma (RCC) tissue samples from patients being treated with immune checkpoint inhibitors (e.g. nivolumab, pembrolizumab, avelumab) to try to identify a biomarker for response to treatment. They found that patients with low levels of a protein-coding gene called PARP1 (poly (ADP-ribose) polymerase […]
Data presented at the American Urological Association (AUA) 2021 meeting last month shows that 5-year survival rates following partial or radical nephrectomy for renal cell carcinoma (RCC) vary depending on the histology of the RCC subtype. The results of this study have implications for developing personalised therapies to target high-risk, aggressive tumours. The researchers identified […]
A large review of the data showed that cancer specific survival and prognosis were improved in renal cell carcinoma (RCC) patients who were overweight or obese compared with patients with a normal body mass index (BMI). Data from 50,717 RCC patients were reviewed in this study. This review showed that cancer specific survival, progression-free survival […]
Active surveillance is increasingly being used for the management of small renal masses. However, questions remain regarding the safety and durability of active surveillance in younger patients. Two hundred and twenty four (224) patients aged 60 or younger were included in the study and followed for an average of 4.9 years. 30.4% of these patients […]
As with most cancers, the psychosocial effects of renal cell carcinoma (RCC) are profound. Around 20% of patients experience depression and 30% experience anxiety due to various reasons, such as treatment side effects, disease-related changes, finances and coping strategies. Not only are these symptoms distressing, they can also affect survival. This was described using two […]
Being overweight or obese is a well-known risk factor for kidney cancer. This study, published in the Journal of Urology, looked at how body mass index (BMI) affects the survival of a total of 50,717 kidney cancer patients. Overweight and obese patients were associated with improved survival compared to patients with normal BMI, while underweight […]
Researchers are constantly looking for biomarkers to help predict which patients will respond to each kidney cancer treatment. A study in Scandinavia has discovered a protein called tumour associated trypsin inhibitor (TATI) that is a biomarker for several tumours and for inflammation. High levels of TATI in the blood predicts an unfavourable outcome for many […]
This study looked at inflammatory biomarkers in the blood for the diagnosis of non-metastatic renal cell carcinoma (RCC). Inflammation is known to be associated with cancer, and there have been a number of studies that have looked at the relationship between cancer and inflammatory biomarkers. Inflammatory biomarkers such as the neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, lymphocyte/monocyte […]
A recent study published in the journal Cancer last month compared the survival of 8,988 kidney cancer patients from the American National Cancer Data Base to assess the impact of cancer spread to the lymph nodes in patients with stage III renal cell carcinoma (RCC). The researchers found that the 5-year survival rate of patients […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
